Spectrum Pharmaceutecals Inc (SPPI)

[antihama]

I would like to see them sell their CASI stock as soon as they can. Makes no sense to me that a small biotech holds stock in another small biotech, especially since we are now disinterested in their drugs. I did't mind them keeping CASI. If CASI succeeds w their strategy it should do wonders w their share price and hence a nice addition to Spectrum's B/S. That's the time I would love for Spectrum to sell their shares. I wouldn't be surprised if Spectrum is prevented from selling per their legal agreement such as for 5 yrs. September will be 5 yrs. You may get to see a sale then and in the meantime we get to see if Evomela is making inroads in China

I would like to see a filing for Rolontis approval in Europe and a follow on co-licensing deal for Europe. Agree but w the nuance that I really don't want to see Spectrum in EU trying to sell Rolontis except if they decide to sell pozi over there too then there might be some efficiencies of scale. That would take a sizable focus on Spectrum's part to get a sales team in place. Having said that I don't want them selling pozi over over there either (just get a nice fat royalty) unless they are getting low balled in licensing out the drug.

I still think JT may be making a mistake with Qapzola. Looks like they are not making any efforts to push the recruiting through. I believe Qapzola is a $100M+ product and they should get it approved and co-license it. This is a bird in hand. Having been a apaz die hard all these yrs, I am saddened by JTs view but I can understand where he is coming from. Just for 5 yrs of sales, I can see him thinking it'll be more of a distraction for selling pozi and Rolontis. I'm not sure if I was still posting on Yahoo or here but after the FDA rejection I was advocating to not start the trial. Oh Oh I almost feel like giving my apaz speal on why the agency should have not rejected the drug; I'd better stop here.

I want them to find another late stage portfolio complimenting drug, but think they need to get Rolontis selling or the PPS up substantially before they can afford a new late stage drug. Perhaps in late 2020. I don't want them distracted until Rolontis is selling and pozi is approved for one indication. I know it's new management but they have so dropped the ball on the other drugs they acquired, I just want them to focus focus focus on Rolontis sales and pozi clinical trials. I don't want them having to decide between starting a promising pozi (combo) trial and buying a new drug. It has to be full steam ahead laser focused on pozi a la SGEN has been doing w Adcetris

SPPI is now positioned to go it alone. We don't need to accept any low ball BO. What I didn't say in my previous post but is really the elephant in the room, is getting rid of the marketed drugs, It has made them that much more attractive to big pharma. Having said that there is NO WAY I can see a buyout. Absolutely not! A buyout might be an immediate gratification to those who've just purchased shares but not to long time longs. No buyout is going to give more than 100% of current value (if that lucky). So no buyout. What we need is a licencing agreement for posi in the EU and co-licencing it here in the US. Once the SP has risen to where it should be then a buyout can be on the table. A perfect example is Loxo's licensing agreement w Bayer and buy out a 1.5 yrs later w Eli Lilly

Fun times and a new beginning.Yessiree!